Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Navigating FDA Shakeups and Obesity Drug Wars

Behind the Headlines Episode 28

Ask the Expert

Closing the Gap in Modern Process Control and Automation for QC/QA

Drug Digest December 2025

How It Helps Avoid Facility and Equipment Problems

A “Plan, Prevent, Prove” Approach

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Retro classic typewriter from circa 1950s with sheet of paper and aged books on wooden desk front aquamarine wall background. Nostalgic writer's work place concept. Vintage old style filtered photo | Image Credit: © BrAt82 - stock.adobe.com

On 6 May 2024, the King’s Awards for Enterprise 2024 winners were announced and included pharmaceutical company, Nanomerics, and several companies that provide services to the pharmaceutical industry. The awards (previously known as the Queen’s Awards for Enterprise) recognize outstanding achievements in enterprise across four categories: innovation; international trade; sustainable development; and promoting opportunity (through social mobility) (1).

Nanomerics, a spin-out from University College London, received the King’s Award for Enterprise in the category of Innovation. The company has been recognized for its active excipient platform for precision medicines, Molecular Envelope Technology (MET). MET works by encapsulating nano-scaled drug doses and allowing water-insoluble compounds to pass through mucosal barriers, which increases efficacy of the drug product and reduces side effects (2).

“It is a real honour to win the King’s Award for Enterprise 2024 in the Innovation category,” said Professor Andreas G. Schätzlein, CEO of Nanomerics, in a press release (2). “This award recognizes the efforts we are making to ensure that drug development has a higher likelihood of success.”

However, the majority of the winners from the pharma industry for 2024 have been recognized for their achievements in international trade. Gentronix, for example, which is a contract research organization that specializes in toxicology, received the award as a result of achieving triple-figure revenue growth thanks to its international expansion (3); and, Seda Pharmaceutical Development Services, which works with biotech companies to help design, develop, and market novel medicinal products, was recognized for its “outstanding short-term growth in overseas sales” (4).

Furthermore, several consulting groups were also recognized in this year’s awards for their successes in international trade. Among these groups were Uptake Strategies, which is a global healthcare consultancy for the pharma and biotech industry (5); and DLRC, which is global consultancy providing regulatory services to pharma and medtech companies of all sizes (6).

The full list of winners for 2024 can be found in a 

1. The London Gazette. The King’s Awards for Enterprise. 

 (accessed 13 May 2024).
2. Nanomerics. Nanomerics Wins the United Kingdom King’s Award for Enterprise 2024. Press Release, 6 May 2024.
3. Tate, M. Genotronix Recognized with King’s Award After Record International Growth. Press Release, 7 May 2024.
4. Seda Pharmaceutical Development Services. Stockport Based, Seda Pharmaceutical Development Services Wins King’s Award for Enterprise 2024. Press Release, 6 May 2024.
5. King, C. Uptake Honoured in the King’s Awards for Enterprise 2024. Press Release, 6 May 2024.
6. DLRC. DLRC Achieves King’s Award for Enterprise in International Trade. Press Release, 6 May 2024.
7. The London Gazette. The King’s Awards for Enterprise. 

Felicity Thomas is the European/senior editor for Pharmaceutical Technology Group.

When referring to this article, please cite it as Thomas, F. Streamlining Variations. 

Articles

Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.

Royal Recognition

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Santander UK, a retail and commercial bank based in the United Kingdom, has announced it has provided Ennogen Healthcare International, a UK-based pharmaceuticals manufacturer, with a £30 million loan to support its international expansion plans. Ennogen, which was established in 2011, is focused on dermatology, respiratory, and pain relief therapies, especially those with chronic conditions. The loan package is intended to support the company’s rapid growth as it invests in purchasing bolt-on pharmaceutical products in appropriate therapeutic areas and targets future acquisitions. The approved funding may be extended to £50 million as Ennogen considers international expansion opportunities, although this is subject to future approvals.

“Santander quickly understood our business and came up with an innovative and flexible approach to meet our acquisition and product development needs,” said Jason Tate, chief financial officer at Ennogen, in a Santander press release (1). “With offices and specialism in key locations around the world, Santander are best placed to support our international expansion strategy. Working with both the team in Manchester and Liverpool, it is clear they have a strong knowledge of the pharmaceutical and healthcare industry.”

Ennogen is based in Dartford and has a regional office in Northwich, Cheshire. Over the past few years, it has grown both organically and through acquisitions, resulting in its current staff totaing over 50 members. Its growth so far has been funded through cashflow and shareholder injections; this loan is intended to give the company a flexible approach to its growth strategy.

“We are delighted to support Ennogen with this new £30m facility, which will help deliver their acquisition plans,” said Sarah Laverty, Structured Finance director at Santander UK in the press release. “The business has a strong management team and clearly articulated strategy, which is exactly the type of business Santander looks to support.”

Santander Provides Pharma Manufacturer Ennogen with £30 Million Credit Facility for Growth

The loan is intended to support Ennogen’s growth as it looks to international acquisitions.

Santander UK Grants £30 Million Loan Package to Ennogen Healthcare

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

In this video, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about aspects of drug product stability.

Drug Digest: Is Our Understanding of Stability Changing

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, interviews Nitin Swarnaker, Pharma Applications Manager, BASF, and Geoff Carr, Former Director, Analytical Development, Thermo Fisher Scientific/Patheonabout various aspects of drug product stability testing. Stability studies involve a drug substance tested under storage conditions and assess its thermal stability and sensitivity to moisture. Over the last decade there has been some intermixing of supply chain storage and distribution systems, and traditional formulations taking these storage and delivery systems into account—continuous monitoring comes to mind. While long-term testing should be performed over a minimum of 12 months at 25 °C ± 2 °C/60% RH ± 5% RH or at 30 °C ± 2 °C/65% RH ± 5% RH. The intermediate and accelerated testing should cover a minimum of 6 months at 30 °C ± 2 °C/65% RH ± 5% RH. Accelerated Predictive Stability (APS) studies, carried out over a 3–4-week period and combining extreme temperatures and RH conditions (40–90 °C)/10–90% RH, have emerged as novel approaches to predict the long-term stability of pharmaceutical products in a more efficient and less time-consuming manner.

Nitin is a Formulation scientist with over 16 years of combined (academic research/training/industrial) experience, and a very strong track record of publications, primarily focused on various formulation aspects of small, peptide and protein molecules for oral and parenteral applications. He has vast experienced in solid, solution, suspension, semisolid products and novel drug delivery systems such as lipid- and polymer-based drug delivery systems (proliposomes and liposomes, liquid crystalline particles nanoparticles and microspheres) including their targeted drug delivery counterparts. He is well-versed in various characterization techniques used in formulation development, possesses a good understanding of various regulatory guidelines and cutting edge concepts and technologies.

Former Director, Analytical Development, Thermo Fisher Scientific/Patheon

Geoff Carr, PhD, has retired after over 45 years experience of working in the pharmaceutical industry and currently provides training and consultancy services to pharmaceutical companies with an emphasis on the application of good chemistry in the development of new pharmaceutical products. Previously, he was appointed as Manager, Analytical Development at Patheon Inc, Canada in 2000 and progressed to Director, Analytical Development, Thermofisher Scientific/Patheon until 2023. Prior to that, he held positions of Manager, Analytical Sciences at Celltech-Chiroscience, UK, Head of Analytical Development at Medgenix, Belgium and before that at Wyeth Research, UK. He originally started his career in pharmaceutical analysis at The British Pharmacopoeia Laboratory where he held several posts and was finally appointed Head of the Laboratory. His academic background is a PhD in synthetic organic chemistry awarded by University of London, UK. He has been a member of various British Pharmacopoeia Committees, a UK representative to Committees of the European Pharmacopoeia and Member of USP Committees including a Member of the 2015-2020 Cycle USP General Chapters – Physical Methods Expert Committee. He is the author of numerous publications including journal articles and book chapters as well as presentations and workshops at international conferences on various topics related to applications of analytical chemistry during the development of pharmaceutical products. This includes a 8 module distance learning course on Pharmaceutical Stability Testing.

This episode of Drug Digest is sponsored by:

Drug Digest is a tech talk video series with the 

® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

 Biologic Drug Development and Manufacturing

Videos

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.

Mike Hennessy Jr. is the Chairman and CEO of 

High Angle Shot of a Working Desk of a Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Research efforts are continuing to expand in the area of biological therapies. These large-molecule drugs are proving to be significant revenue drivers for bio/pharma companies and are providing therapeutic options for disease areas that have previously suffered from unmet medical needs (1).

Additionally, biologics are useful in providing more targeted disease treatment when compared with small-molecule drugs and lessening the risk of side effects for patients. The targeted nature of these large-molecule therapies is explored in this issue’s cover story, featured on pages 10–13, along with the potential that technological advances hold in pushing future boundaries and some of the challenges facing both the development and manufacture of biologic drugs (2).

Advanced therapy medicinal products (ATMPs), which are promising and often curative biologic therapies, face their own specific development and manufacturing challenges. Scalability of manufacturing for these emerging therapies is a particular bottleneck and something that San Francisco-based Cellares, a self-titled integrated development and manufacturing organization (IDMO), has sought to change. In an interview with Pharmaceutical Technology® Group, Fabian Gerlinghaus, CEO and co-founder of Cellares, detailed how the company’s Cell Shuttle platform and integrated consumable cartridge automated platform can improve scalability of ATMP manufacturing (3).

The IDMO has also garnered interest from Bristol Myers Squibb (BMS), which joined the Technology Adoption Partnership (TAP) program in August 2023 (4). Participation in the TAP program has meant that BMS can use Cellares’ automated manufacturing platform for the manufacture of its pipeline products.

Most recently, in April 2024, BMS and Cellares built upon their relationship by entering into a deal worth $380 million, where Cellares will transfer select chimeric antigen receptor T-cell therapies onto its manufacturing platform, with the aim of meeting growing demand and improving turnaround time (5).

1. Bender, M. Pharmaceutical & Life Sciences Trends 2024. 

 (accessed April 24, 2024).
2. Thomas, F. Biologics On Target for the Future. 

, 48 (5), 10–13.
3. Spivey, C. Cellares Innovates with Automated Cell and Gene Therapy Platform. 

, March 7, 2024.
4. Cellares. Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform. Press Release, Aug. 28, 2024.
5. Cellares. Bristol Myers Squibb and Cellares Announce a $350M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster. Press Release, April 22, 2024.

Mike Hennessy Jr. is the President and CEO of 

When referring to this article, please cite it as Hennessy, M. Tapping into the Potential of Biologics. 

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Tapping into the Potential of Biologics

FDA’s Center for Drug Evaluation and Research (CDER) has published the 2023 Office of New Drugs (OND) Annual Report. The report details the office’s major achievements of 2023, including notable drug approvals, publications, guidances, workshops, webinars, and meetings. Specifically, these achievements contain over 3400 formal meetings between sponsors of new drug development programs and CDER staff; 25 public Advisory Committee meetings; 55 novel drug approvals; 34 issued guidances; 651 OND speaking engagements; and OND representations at meetings, including Patient-Focused Drug Development meetings, Critical Path Innovation meetings, and Patient Listening Sessions.

Also featured are innovations in drug design and development, as well as OND’s partnerships with FDA and external stakeholders to tackle obstacles in drug development and regulation. The report demonstrates OND’s efforts in supporting drug development, pushing forward important drug approvals through substantial application reviews, using workshops and new guidances to promote policy, and maintaining careful post-approval drug assessments.

The report is largely divided into individual office reports, including the offices of: cardiology, hematology, endocrinology, and nephrology (OCHEN); drug evaluation sciences (ODES); immunology and inflammation (OII); infectious diseases (OID); neuroscience (ON); nonprescription drugs (ONPD); oncologic diseases (OOD); rare diseases, pediatrics, urologic and reproductive medicine (ORPURM); specialty medicine (OSM); therapeutic biologics and biosimilars (OTBB); and the non-clinical offices of program operations (OPO), regulatory operations (ORO), administrative operations (OAO), and new drug policy (ONDP). Each section includes a brief overview of the department, followed by its major achievements from the year. The report also features a message from the director, OND’s senior leadership team, an organizational chart of the office, publications from each office, and a list of acronyms and key terms.

Over 2023, OND organized 21 patient listening sessions, 18 of which were organized with the office of the commissioner and the office of patient affairs, and 3 of which were organized with professional affairs and stakeholder engagement. OND’s drug approvals in 2023 included new molecular entity (NME) new drug applications (NDAs), and biologics applications (BLAs), with additional efficacy supplement approvals and approvals to breakthrough therapy requests and fast track requests.

“This report documents the diverse efforts of OND staff, beyond the regulatory actions to approve important drugs,” stated Peter Stein, Director, Office of New Drugs in the report (1). “These efforts include holding many public meetings both to inform our OND staff of cutting edge science, and for OND staff to contribute to the knowledge of those in the pharmaceutical industry, in academics, and for patients and other stakeholder groups about advances in regulatory science, the biology of disease, and advances in clinical drug development; publishing numerous guidances that give insight to drug developers about the pathways and approaches to development that can provide the data FDA needs to support the effectiveness and safety of new drugs; the careful monitoring of drug safety post-approval to assure that drug’s prescribing information is kept updated with the safety information that health care practitioners and patients need.”

Center for Drug Evaluation and Research (CDER), 

2023 OND Annual Report: Breaking Barriers to Advance Public Health

The report covers the major achievements of the office during 2023, including notable drug approvals, publications, guidances, workshops, webinars, and meetings.

CDER Releases Office of New Drugs 2023 Annual Report

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Q: We read in an article (1) that there are no specific good manufacturing practice (GMP) regulations for emerging therapies in the United States, yet we wish to bring our emerging therapy products to the US market. How can we make sure our products comply with current regulations?

A: In the absence of specific regulations for your products, the existing generic regulations, such as 21 Code of Federal Regulations (CFR), 600 Biological Products (2), will apply as appropriate. Also, international harmonized guidelines, such as International Council for Harmonisation (ICH) Q9(R1) Quality Risk Management and ICH Q10 Pharmaceutical Quality System (3,4) need to be followed and complied with. However, these are not the only sources of regulatory information available. FDA has published guidance on cellular and gene therapy products (5), which includes guidance and information on “Regenerative Medicine Advanced Therapy Designation” and on “Interactions with Office of Tissues and Advanced Therapies”.

Companies, especially developers of new types of drugs, are encouraged to interact with the regulatory authorities early on in the drug development cycle, and FDA is no exception. There are multiple opportunities for formal as well as informal meetings with FDA, and FDA’s website provides an excellent overview, including links to further information (6).

There is more information out there, free of charge, and most likely relevant to the products your company is currently developing. Though international regulations are only harmonized to some degree, there is generally a broad consensus on the basic principles of GMP, be it for traditional drug products or novel, emerging therapy products. Therefore, companies should look at regulations from other regions (e.g., the European Union [EU]) and guidance from key agencies, such as the European Medicines Agency (EMA). The EU have issued specific regulations for advanced therapy medicinal products (7), recognizing the need to address compliance for these products separately. The GMP requirements detailed in here will broadly be the same that FDA expects. Aspects that require further guidance and clarification are often covered in “Questions & Answers” documents published by EMA. An EMA Q&A document published in 2011 (8) discusses, for example, how to identify the minimum GMP requirements for starting materials, considering quality management, quality risk management, product development, production, and quality control.

These are just a few pieces of information in response to your question. There is much more information available online, from specialist publications, subject matter experts, and not least directly from the regulatory agencies through their consultation mechanisms.

Thomas, F. Optimizing the Manufacture of Emerging Therapies. 

FDA. Interactions with Office of Therapeutic Products. 

EC. Part IV, GMP requirements for Advanced Therapy Medicinal Products. 

Questions and Answers on the Principles of GMP for the Manufacturing of Starting Materials of Biological Origin Used to Transfer Genetic Material for the Manufacturing of ATMPs,

When referring to this article, please cite it as Schmitt, S. GMPs for Emerging Therapies.

Guidance documents and interaction with FDA can help manufacturers stay in GMP compliance, says Siegfried Schmitt, VP Technical, at Parexel.

Emerging Therapies and GMPs

Feliza Mirasol is the science editor for 

FDA's Center for Biologics Evaluation and Research (CBER) has issued a new draft guidance, 

Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products 

(1). The document was issued in April 2024.

According to FDA in an April 30, 2024 notice in the 

 (2), “Allogeneic cells of human origin may be expanded in culture to manufacture medical products consisting of live cells, inactivated cells, cell lysates, or other cell-based materials such as cell-derived particles.” Thus, the draft guidance provides recommendations to help sponsors of allogeneic cell-based medical products determine what cell safety testing is appropriate to support an investigational new drug application (IND) or a biologics license application (BLA).

The agency notes that cell safety testing should be based on a risk analysis that considers the expansion potential of the cells in addition to the reagents that are used to expand these cells in culture as well as the number of individuals capable of treatment with the cell-based medical product.

Allogeneic cell-based products that are regulated by CBER’s Office of Therapeutic Products are subject to this new guidance. It applies to cultured allogeneic cells—including cell banks—that serve as sources of intended constituents for the final drug product. The guidance also applies to combination products that contain an allogeneic cell or cell-based biologic component in combination with a drug and/or device.

“The recommendations in this guidance also apply to genetically modified allogeneic cells that have been transduced with viral and/or plasmid vectors, and cells that have undergone genome editing. This guidance does not apply to cell substrates that are used during manufacturing of non-cell-based products such as viruses, gene therapy vectors, or recombinant proteins,” the draft guidance document states (1). However, the document emphasizes that recommendations for feeder or other cells used as reagents during manufacturing are beyond the scope of this particular guidance.

FDA is accepting comments on the draft guidance either electronically or in writing until the deadline of July 29, 2024, after which time it will begin work on the final version of the guidance (2).

FDA has stated that this new draft guidance is intended to supplement two other final industry guidance documents, 

Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)

Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)

Draft Guidance for Industry, Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products

Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products; Draft Guidance for Industry; Availability

Guidance for Industry, Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)

. Guidance for FDA Reviewers and Sponsors, Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)

In the new draft guidance, FDA provides recommendations on cell safety testing of human-sourced allogeneic cells for sponsor companies.

New FDA Draft Guidance Issued for Sponsors of Allogeneic Cell-Based Medical Products.

Adare Pharma Solutions, a global contract development and manufacturing organization (CDMO) focused on oral dosage forms, has announced plans to expand its high potency handling capabilities in the United States and Europe. This expansion will include a second high potency suite to Adare’s facility in Philadelphia, upgrades to R&D suites in its Ohio facility, and high potency upgrades to its facility in Milan, Italy.

Adare’s 128,000 sq ft Orthodox Street facility in Philadelphia will receive a second high potency suite, which will add encapsulation, blending, high-shear granulation, and other manufacturing processes. These processes will bolster the site’s existing potent suite, which provides bin blending, roller compaction, milling, and tablet compression. Construction is set to complete by Q4 of 2024.

Work has already begun on the company’s 179,000 sq ft Vandalia facility in Ohio and is also scheduled to complete by Q4 of 2024. The Ohio facility is receiving upgrades to several of its R&D-to-clinical stage production suites to provide high potency handling. Capabilities will include microencapsulation, dry roller compaction, and fluid bed processing.

The expansion to Adare’s 220,000 sq ft Pessano facility in Milan, Italy will add high potency upgrades to its formulation and analytical laboratories, which include bin blending, fluid bed processing, compression, encapsulation, and pan-coating capabilities. Additionally, the facility recently announced plans to add packaging capabilities and more warehouse capacity (2). A two-story, 2800 square-meter extension is underway to accommodate a new packaging line in a specially built packaging hall, which is projected to be installed by Q4 2024. The expansion also contains a 1000 square-meter warehouse with capacity for 900 pallets and space for a second future packaging line.

A week after its packaging and warehouse expansions were announced, Adare revealed further expansions to the Milan site, adding a high-shear mixer granulator to its existing fluid bed capabilities (3). The granulator, an IMA 600-L Roto Mix high-shear mixer with IMILL and Hydrowash, provides wet granulation with either aqueous or organic-based solutions. The mixer’s design allows for lower changeover times and lower water and energy consumption as compared to traditional machine clean-down routines. These expansions, as well as the high potency upgrades, are expected to be operational by the end of 2024.

“We have seen demand for high potency handling and packaging continue to increase, with around half of solid dose drugs in development being highly potent,” said Tom Sellig, CEO of Adare Pharma Solutions, in a company press release (1). “This proactive investment across our global network of sites will ensure we continue to provide customers with the oral dose capabilities and capacity they will need both now and in the future.”

Adare Pharma Solutions, Adare Expands Global High Potency Handling and Packaging Capabilities. Press Release, May 1, 2024.

Adare Pharma Solutions, Adare Pharma Solutions to Expand Packaging and Warehousing Capabilities in Europe. 

Adare Pharma Solutions, Adare Pharma Solutions Expanding Oral Dose Capabilities in Europe. 

The CDMO plans to expand and upgrade its Philadelphia, Ohio, and Milan facilities to meet the continued growth in demand for high potency handling capabilities.

Adare Expands High Potency Handling Capabilities in US and Europe

ROSS V Cone Blenders utilize diffusion as the main mechanism for mixing. As the V-shaped vessel rotates on its horizontal axis, batch materials cascade down, distributing particles over a freshly exposed surface. Operating at speeds of 5 to 25 revolutions per minute, the ROSS line of tumble blenders can mix dry solid blends (including high density powders), low-viscosity slurries, friable materials, and formulations containing trace components and ingredients that are dissimilar in size, shape, and density.

The pictured ROSS Model VCB-20 includes two pneumatic cylinders affixed to the V cone body to disconnect and connect fiber drums for charging and discharging. The blender’s butterfly valve is operated by optional pneumatic control. A high-speed intensifier bar is installed along the mixer’s axis of rotation to reduce agglomerates, and nozzles can be attached to it for continuous liquid additions during mixing. The model also includes carbon steel legs with 40” clearance beneath the discharge valve to the floor, and safety guardrails at the front and rear of the mixer.

Charles Ross & Son's ROSS V Cone Blenders utilize diffusion as the main mechanism for mixing.

V-Shaped Cone Tumble Blender

Deitz’s Pharmafill TC4 tabletop tablet counter includes an automatic feeder control system to ensure a consistent volume of tablets is fed onto a rotating disc for feeding to the counting sensor. The automatic feeding system features a proximity sensor assembly that automatically stops the flow of tablets from the hopper if the flow rate exceeds the pace of the operator filling the bottles. When ready for additional tablets, the system automatically restarts the vibratory feeder and restores product flow at the preset rate.

The TC4 is suitable for counting and filling capsules, gelcaps, pills, softgels, and other opaque, translucent, and transparent oral solid dosage forms. The compact electronic tablet counter achieves filling rates of up to 2000 tablets per minute, filling bottles up to 10 inches in height. The semi-automated pill counting machine comes with a two-year warranty and arrives ready to plug in to common 110 VAC electrical services.

Deitz’s Pharmafill TC4 tabletop tablet counter is suitable for counting and filling capsules, gelcaps, pills, softgels, and other opaque, translucent, and transparent oral solid dosage forms.

Featured Content

Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Behind the Headlines Episode 28

Ask the Expert

Drug Digest December 2025

A “Plan, Prevent, Prove” Approach